loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ravidasvir

    Client Email Product
    dr-reddy-s-laboratories-2024-09-02

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    View Presentation

    Send me more info on How To Grow My Business Digitally?
    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    SPI Pharma Corp Ad

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Ravidasvir

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 69Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Malaysia set to become Hepatitis C treatment hub of Asia
    Malaysia set to become Hepatitis C treatment hub of Asia

    16 Nov 2021

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/30/19355/malaysia-set-to-become-hepatitis-c-treatment-hub-of-asia.html

    BIOSPECTRUMASIA
    16 Nov 2021
    Share Share
    Ascletis' All-oral HCV Treatment Approved for Marketing in China
    Ascletis' All-oral HCV Treatment Approved for Marketing in China

    31 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-all-oral-hcv-treatment-approved-for-marketing-in-china-301103622.html

    PRNEWSWIRE
    31 Jul 2020
    Share Share
    WHO HCV Guidelines recommends Ascletis' Ravidasvir
    WHO HCV Guidelines recommends Ascletis' Ravidasvir

    09 Aug 2018

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/25/11475/who-hcv-guidelines-recommends-ascletis-ravidasvir.html

    BIOSPECTRUM
    09 Aug 2018
    Share Share
    Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA
    Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

    02 Aug 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-nda-for-its-all-oral-hcv-treatment-accepted-by-cfda-300690036.html

    PR NEWSWIRE
    02 Aug 2018
    Share Share
    Making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO
    Making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO

    18 Jul 2018

    // Amber Tong ENDPTS

    https://endpts.com/on-its-way-to-making-hong-kong-history-ascletis-eyes-457m-haul-in-gic-backed-ipo/

    Amber Tong ENDPTS
    18 Jul 2018
    Share Share
    Epclusa's fast-tracked Chinese approval might be late for Gilead
    Epclusa's fast-tracked Chinese approval might be late for Gilead

    31 May 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded

    Angus Liu FIERCE PHARMA
    31 May 2018
    Share Share